PRT062607 (Hydrochloride)

1370261-97-4

C19H24ClN9O

DMSO : >= 33 mg/mL (76.76 mM)

Protein Tyrosine Kinase/RTK

PRT062607 Hydrochloride (P505-15 Hydrochloride) is a highly specific and potent inhibitor of purified Syk (IC₅₀ 1-2 nM). IC50 & Target: IC50: 1 nM (Syk), 81 nM (Fgr), 88 nM (MLK1), 123 nM (Yes)^[1] In Vitro: PRT062607 (P505-15) is a novel, highly specific, and potent orally available small-molecule inhibitor of Syk. The potency of PRT062607 against its target kinase Syk is initially tested in two different purified kinase assays. Using a FRET assay, half-maximal Syk inhibition required 6+/-0.2 nM (mean+/-S.E.M.). Similar potency is observed when tested in a radioactive enzyme assay, with a resulting Syk IC₅₀ of 2.1+/-0.4 nM (mean+/-S.E.M.). In human whole blood, PRT062607 potently inhibits B cell antigen receptor-mediated B cell signaling and activation (IC₅₀ 0.27 and 0.28 uM, respectively) and Fcepsilon receptor 1-mediated basophil degranulation (IC₅₀ 0.15 uM)^[1]. In Vivo: In the mouse CAIA model, oral administration of PRT062607 (P505-15) results in an average inhibition of paw inflammation, as measured by daily scoring of inflammation compared with vehicle controls, of 12, 44, and 87% with average plasma concentration (C average over 24 h) assessed at the end of the study of 0.38, 0.95, and 1.47 uM, respectively. In mice treated with 30 mg/kg PRT062607, the damage to the joints is significantly reduced and seemed indistinguishable from normal mice. In the rat CIA model, the high dose of PRT062607 (15 mg/kg b.i.d.) completely suppresses inflammation in a majority of the animals (seven of eight), by the end of the study (mean inflammation score+/-S.E.M.=0.63+/-1.1; p<0.0001 versus vehicle)^[1].